智通财经APP获悉，如何让复杂的临床试验对参与者更"友好"，对管理者更"高效"？动动手指，临床试 验的访视安排、报销进度、用药服务即可一键掌握——这已不再是设想。近日，医渡科技(02158)与北 京大学肿瘤医院联合打造的临床试验管理体系(CTMS)移动端——"北肿临床试验"小程序正式上线。这 不仅将"以患者为中心"的理念落到了实处，更标志着临床试验管理在参与者体验、数据安全与执行效率 上实现了全面升级。 体验三大升级：让临床试验参与"省心又安心" 本次新上线的CTMS小程序是以试验参与者体验为出发点，实现从"管理导向"向"服务导向"的升级突 破，其深度融入微信生态，在移动端场景下为试验参与者带来了诸多便利： 在此坚实而广泛的合作基础上，CTMS临床研究管理系统作为一个符合GCP标准的全链路数智化管理平 台，为北肿提供了从项目立项、执行到结题的一站式解决方案。其价值已在实践中得到充分验证：通过 系统的流程标准化与全周期精细管控，北肿临床试验项目的平均立项启动时间显著缩短，效率优于行业 平均水平。 这一系列以参与者为中心的改进，标志着临床试验数字化从侧重机构内部流程管理，向兼顾外部参与者 服务体验的成功延伸。 该 ...

大模型重塑千行百业的今天，医疗领域却面临一个现实命题：当通用AI遇上临床的 "严谨刚需"，如何让算法真正听懂医生的话、嵌入诊疗的流程？这正是 医疗AI从"可用"走向"实用"的核心关卡。 智通财经APP获悉，近日，医渡科技（02158）高级副总裁、科研业务线总经理黄楠博士，技术创新副总裁、AI架构师李林峰博士共同出席中国老年保健医 学研究会数智健康分会2025年会暨清华心血管教育培训课程，以"大模型临床助手赋能专科诊疗提质增效"为核心，分享了医渡科技的深耕实践。 人工智能与医疗健康领域的融合正在全面提速。然而，通用大模型在直接服务临床决策时，面临"幻觉"风险、过程不透明、缺乏医疗严谨性等根本问题。 医渡科技的解题思路，是进行一场面向临床实用性的系统性重构，让AI的"思考"过程变得可控、可信、可溯源。公司以自研医疗垂域大模型"YiduCore"为核 心，打造了"大数据+大模型"双中台解决方案，为医院打造高质量发展的坚实数字底座。 其中，AI中台的核心价值，在于可将大模型的原始能力系统性转化为符合医疗规范、理解临床流程、知晓专科知识的"智能体"，从而实现AI在真实医院场景 中的"落地生根"。 让智能伙伴无缝融入工作 ...

Core Viewpoint - The company demonstrates strong confidence in its intrinsic value and long-term development through frequent share buybacks, signaling positive financial health and operational capabilities [1][2]. Group 1: Share Buyback Activity - The company has conducted its 10th share buyback announcement this month, repurchasing 190,000 shares at a price of HKD 5.13 per share, totaling approximately HKD 1 million [1]. - Cumulatively, the company has repurchased 3.34 million shares in December, amounting to around HKD 17 million [1]. - Frequent and sustained buyback operations reflect the company's belief that its current stock price is undervalued [2]. Group 2: Business Development and Industry Engagement - The company has joined the Health Sustainable Development Working Committee under the Shanghai Cooperation Organization's economic platform, enhancing its role in international healthcare collaboration and innovation [1]. - The company has surpassed 3 million participants in the "Beijing Universal Health Insurance" program for 2026, showcasing its strong operational capabilities and market recognition in the health insurance sector [1]. - The company has been elected as the vice-chair unit of the Smart Healthcare Working Committee of the China Internet Association, further solidifying its industry influence and technological leadership [1]. Group 3: Financial Performance - The company reported steady revenue growth in its mid-term results for the 2026 fiscal year, nearing breakeven [1]. - Significant improvement in key financial metrics is attributed to the continuous increase in gross margin of core business and enhanced operational efficiency [1]. - The company's improved financial health reflects its strengthened commercialization capabilities and substantial progress in operational quality [1].

同时，公司近期当选为中国互联网协会智慧医疗工作委员会的副主委单位。 近期，医渡科技在业务拓展与行业共建方面动作频频。公司正式加入上海合作组织经贸平台下设的卫生 可持续发展工作委员会，将在国际框架下更多地参与推动医疗健康领域的合作与创新。 在国内市场，由医渡科技担任主运营方的2026年度"北京普惠健康保"参保人数突破300万，展现了其在 惠民保业务领域的运营能力。 12月18日，医渡科技(2158.HK)发布本月以来第10次回购公告，当日以每股5.13港元的价格回购19万 股，回购金额约100万港元。12月以来已累计回购334万股，总金额约1700万港元。 业内认为，高频次、持续性的回购操作，旨在显示公司对内在价值及长远发展的坚定信心。 日前发布的2026财年中期业绩显示，医渡科技收入保持增长，期内几近实现盈亏平衡。这一关键财务指 标的优化，主要得益于公司核心业务毛利率的持续提升以及运营效率的不断改善，反映出其商业化落地 能力增强和经营质量的实质性进步。 有资本市场人士认为，密集的回购行为，往往体现了公司对当前股价低估的判断，也预示着其财务实力 足以支撑未来战略投入与持续发展。上市公司的连续回购与近期一系列进展 ...

收入止跌回升 医渡科技第二和第三季度毛利1.34亿元，毛利率由35.6%升至37.4%，归属母公司净亏损1460.2万元，每 股亏损0.01元，已接近盈亏平衡。 分业务看，大数据平台和解决方案当期收入1.53亿元，同比增加14.6%；生命科学解决方案收入1.38亿 元，小幅下降4.4%；健康管理平台和解决方案收入0.67亿元，增长30.3%。医渡科技表示，大数据平台 板块增长主要受益于政策驱动下业务机会扩大，而生命科学板块受医药行业周期波动影响略有下滑；健 康管理板块的高增速则源于产品组合调整和惠民保等保险项目放量。 营收增长同时，医渡科技成本费用增幅受控。公司当期销售及服务成本2.2408亿元，同比增长5.6%，低 于收入增速。三项期间费用合计1.684亿元，与上年同期基本持平，占收入比重由67.8%降至61.1%。其 中研发开支8，478.5万元，同比减少9.5%，公司称，主要因为外部技术和咨询服务费用削减，体现聚焦 核心研发投入的策略。 截至9月30日，医渡科技现金及现金等价物、定期存款和受限制资金合计约20.993亿元，较财年初减少 约12亿元。其中主要由于公司将部分资金转投按摊余成本计量的长期投资（ ...

本文源自：市场资讯 作者：公告君 回购日期回购均价回购股数回购金额本年累计回购股数2025-12-185.12819.00万97.44万723.13万2025-12- 174.98140.00万199.23万704.13万2025-12-164.94464.08万316.83万664.13万2025-12-125.10115.50万79.07 万600.05万2025-12-115.01253.50万268.16万584.55万2025-12-095.15134.50万177.70万531.05万2025-12- 085.23722.50万117.82万496.55万2025-12-055.18328.00万145.12万474.05万2025-12-045.14718.10万93.16 万446.05万2025-12-035.09039.20万199.53万427.95万2025-10-245.6462.12万11.97万388.75万2025-10- 235.54335.00万194.02万386.63万2025-10-225.6391.77万9.98万351.63万2025-10-215.7015.96 ...

Group 1 - The company has conducted its 10th share buyback announcement in December, repurchasing 190,000 shares at a price of HKD 5.13 per share, totaling approximately HKD 1 million [1] - Cumulatively, the company has repurchased 3.34 million shares in December, with a total expenditure of around HKD 17 million, indicating strong confidence in its intrinsic value and long-term development [1] - The company has joined the Health Sustainable Development Working Committee under the Shanghai Cooperation Organization's economic platform, enhancing its role in international healthcare collaboration and innovation [1] Group 2 - The company has surpassed 3 million participants in the "Beijing Universal Health Insurance" program for 2026, showcasing its strong operational capabilities and market recognition in the health insurance sector [1] - The company has been elected as the vice-chair unit of the Smart Healthcare Working Committee of the China Internet Association, further solidifying its industry influence and technological leadership [1] - Financially, the company has shown positive signs of improvement, with revenue maintaining steady growth and nearing breakeven in its mid-term results for the 2026 fiscal year, attributed to improved gross margins and operational efficiency [1] Group 3 - Analysts suggest that the company's frequent buyback actions reflect a judgment of its current stock price being undervalued and indicate financial strength to support future strategic investments [2] - The continuous buybacks and recent developments send a positive signal to the market, aligning with the trend of deep integration of artificial intelligence and healthcare [2] - The company's established barriers through deep layout and innovative practices are making its long-term investment value increasingly clear as performance inflection points approach [2]

本文源自：智通财经网 智通财经讯，医渡科技(02158)发布公告，于2025年12月18日，该公司斥资97.44万港元回购19万股股 份，每股回购价格为5.1-5.16港元。 ...

Core Viewpoint - The company demonstrates strong confidence in its intrinsic value and long-term development through frequent share buybacks, signaling positive financial health and operational capabilities [1][2]. Group 1: Share Buyback Activity - The company announced its 10th share buyback in December, repurchasing 190,000 shares at HKD 5.13 per share, totaling approximately HKD 1 million [1]. - Cumulatively, the company has repurchased 3.34 million shares in December, amounting to about HKD 17 million [1]. - Frequent and sustained buyback operations reflect the company's belief in its undervalued stock price and financial strength to support future strategic investments [2]. Group 2: Business Development and Industry Engagement - The company has joined the Health Sustainable Development Working Committee under the Shanghai Cooperation Organization's economic platform, enhancing its role in international healthcare collaboration [1]. - As the main operator of the "Beijing Universal Health Insurance" program, the company has surpassed 3 million insured participants, showcasing its strong operational capabilities in the public health insurance sector [1]. - The company has been elected as the deputy chairman unit of the Smart Healthcare Working Committee of the China Internet Association, further solidifying its industry influence and technological leadership [1]. Group 3: Financial Performance - The company reported steady revenue growth in its mid-term results for the fiscal year 2026, nearing breakeven [1]. - Significant improvement in key financial metrics is attributed to the continuous increase in gross margin of core business and enhanced operational efficiency [1]. - These financial indicators reflect the company's improved commercialization capabilities and substantial progress in operational quality [1].

格隆汇12月18日丨医渡科技(02158.HK)公告，12月18日耗资97.4万港元回购19万股。 ...